Gemcitabine
Product Images NDC 72485-221

7 FDA label images from Armas Pharmaceuticals Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gemcitabine (NDC 72485-221). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Armas Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Carton (Carton1)

Carton (Carton1)
Outer carton label for Gemcitabine Injection 200 mg/5.26 mL (38 mg/mL), a single dose vial for intravenous infusion only. The label warns that the product must be diluted before use and stored at 2 to 8°C (36 to 46°F). It includes caution about cytotoxicity. Manufactured by Shilpa Medicare Limited, India, and distributed by Armas Pharmaceuticals Inc., Manalapan, NJ.*
FDA Label Image

Structural Formula (Image01)

Structural Formula (Image01)
Chemical structure of Gemcitabine hydrochloride showing its molecular components, including fluorine atoms, hydroxyl groups, and an aromatic ring with amine and carbonyl substituents.*
FDA Label Image

Figure 1 (Image02)

Figure 1 (Image02)
A Kaplan-Meier survival curve showing progression-free probability over time in months for two treatment groups: Gemcitabine/Carboplatin (N=178) and Carboplatin alone (N=178). The curve compares progression-free survival, with Gemcitabine/Carboplatin showing longer median survival (8.6 months) compared to Carboplatin (5.8 months). A log-rank test p-value of 0.0038 is included.*
FDA Label Image

Figure 2 (Image03)

Figure 2 (Image03)
A survival curve graph depicting progression-free probability over time in months for two treatment groups: Gemcitabine/Paclitaxel (N=178) and Paclitaxel alone (N=262). The chart displays median time to documented disease progression, with 5.2 months for the combination and 2.9 months for Paclitaxel, including a log-rank p-value less than 0.0001.*
FDA Label Image

Figure 3 (Image04)

Figure 3 (Image04)
A Kaplan-Meier survival curve chart comparing survival probability over time (months) for two treatment groups: Gemcitabine/Cisplatin (N=260) and Cisplatin alone (N=262). The chart includes median survival times (9.0 months for Gem/Cis, 7.6 months for Cis) and 1-year survival percentages (39% for Gem/Cis, 28% for Cis), along with p-values for Logrank (0.008) and Wilcoxon (0.018) tests.*
FDA Label Image

Figure 4 (Image05)

Figure 4 (Image05)
A survival curve chart comparing Gemcitabine and 5-FU showing fraction surviving on the vertical axis and survival time in months on the horizontal axis. The graph illustrates survival trends over approximately 20 months, with Gemcitabine maintaining higher survival fractions than 5-FU.*
FDA Label Image

Vial (Vial1)

Vial (Vial1)
Inner vial label for Gemcitabine Injection 200 mg per 5.26 mL (38 mg/mL) by Armas Pharmaceuticals Inc. The label states the vial contains 200 mg gemcitabine equivalent to 227.7 mg gemcitabine hydrochloride, with water for injection. It highlights storage instructions of 2 to 8°C and emphasizes dilution before use. The product is manufactured by Shilpa Medicare Limited, India, and distributed by Armas Pharmaceuticals, Inc., Manalapan, NJ, USA. The label cautions that the agent is cytotoxic.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.